ArticleBMJ open2026
LED red light for atrophy and microcirculation in pathologic myopia (RAMP): study design and protocol for a multicentre randomised controlled trial.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07312214 (A Randomized Controlled Trial of LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial of LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPathologic myopia (PM) is a leading cause of irreversible blindness worldwide, yet effective therapeutic interventions remain limited. Although repeated low-level red light (RLRL) therapy has demonstrated significant efficacy in controlling myopia progression among children, its application in patients with PM remains unexplored. This study aims to evaluate the regulatory effects of RLRL on choroidal vascular density and thickness in patients with PM and verify its safety and efficacy in delaying the progression of fundus atrophic lesions. METHODS AND ANALYSIS: This is a prospective, randomised, controlled trial enrolling 158 patients with PM aged 18-55 years. Participants will be randomised (1:1) to an intervention group or a control group. The intervention group will receive light-emitting diode-based RLRL therapy (wavelength, 660 nm; power density, 65 mW/cm²) administered two times daily for 3 min per session, 5 days per week, over a 12-month period. The control group will receive a sham treatment (power density, 5 mW/cm²) following an identical schedule. The primary outcome measure is the change in choroidal vascular density and choroidal vessel volume index at 12 months. ETHICS AND DISSEMINATION: This study has been approved by the Ethics Review Committee of Shanghai Eye Disease Prevention and Treatment Centre (EC-20250506-04). This study will be conducted in adherence to the approved protocol, Good Clinical Practice and the Declaration of Helsinki. The study results will be submitted to a peer-reviewed journal and presented at both local and international congresses. TRIAL REGISTRATION NUMBER: NCT07312214.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.